Skip to main content
. 2018 Jan 2;50(4):1252–1259. doi: 10.4143/crt.2017.438

Table 2.

Response to dovitinib

Endpoint Rate (95% CI, %)
16-Week PFS rate 42.1 (27.9-57.8)
Objective response rate 12.5 (5.0-28.1)
Disease control rate 59.4 (42.4-76.4)
PSA response rate 12.9 (1.3-25.4)

CI, confidence interval; PFS, progression-free survival; PSA, prostate specific antigen.